Close

LANXESS India donates disinfectants to Thane Municipal Corporation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...
- Advertisement -

To help fight the current COVID-19 pandemic in India, specialty chemicals company LANXESS India has donated its highly effective Rely+On™ Virkon™ disinfectant to Thane Municipal Corporation (TMC) to reduce the cross contamination of COVID-19 in civic hospitals and other establishments.

Rely+On™ Virkon™ inactivates coronavirus quickly
With regard to the current global Coronavirus situation, independent tests have proven that Rely+On™ Virkon™ quickly inactivates a closely related surrogate of the currently spreading coronavirus strain. From these tests it can be concluded that Rely+On™ Virkon™ would also be effective against SARS-CoV-2 which is causing the current COVID-19 epidemic.

The independent test results indicated that Rely+On™ Virkon™ achieved inactivation of the coronavirus strain at a 1:100 dilution rate with a 10-minute contact time. This corresponds to test conditions required by the U.S. Environmental Protection Agency (EPA) and proves the performance and suitability of Rely+On™ Virkon™ for practical use.

Rely+On™ Virkon™ is diluted for application and sprayed on hard surfaces and equipment. It can therefore help to reduce the risk of cross contamination from surfaces, door handles, tables or chairs during disinfection measures at public transport terminals, airports, hospitals, clinics, shopping malls, etc.

Due to this wide application range, there has been a significant increase in demand from the Indian industry as many private hospitals and several corporations have placed significant orders of the disinfectant in their own efforts to limit the spread of the disease in their organizations.

Neelanjan Banerjee, Vice Chairman and Managing Director, LANXESS India commented, “We are working concertedly to ensure that our production and logistics capacities are optimally aligned to cater to the surge in demand for Rely+On Virkon. We are committed to fully utilize our product expertise to help fight the spread of COVID-19.”

About LANXESS
LANXESS is a leading specialty chemicals company with sales of EUR 6.8 billion in 2019. The company currently has about 14,300 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment

Cancer is no longer viewed solely as a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »